正在加载视频...

视频加载失败

返回首页

🔍 Ultrasound-Guided Lumbar Puncture – an essential POCUS technique for improving procedural success in CSF sampling, especially in ↑BMI or anatomically challenging patients with spinal deformities or prior surgeries, minimizing traumatic taps, needle redirects, and complications to enhance diagnostic accuracy and patient safety in emergency, neurology, and critical care...

POCUSpeek's profile picture

POCUSmedicine

10,372 subscribers

20,111 次观看 • 11 个月前 •via X (Twitter)

健康养生科学技术教育
LIVE

Anya Rossi• Live Now

Private livecam show

0 条评论

暂无评论

原始帖子的评论将显示在这里

相关视频

🔍 Check out the DIVOT Protocol — a simple yet powerful way to use Doppler with thoracic ultrasound to spot vessels before procedures like thoracentesis. By blending Doppler imaging with thoracic ultrasound, this protocol offers procedural clarity and boosts patient safety. A must-read for clinicians that could make a big difference in your next case! 📖 Read more: 🦋 Follow us on BlueSky: #Ultrasound #POCUS #POCUSJournal #Procedures #MedTwitter #MedEd
0:50

🔍 Check out the DIVOT Protocol — a simple yet powerful way to use Doppler with thoracic ultrasound to spot vessels before procedures like thoracentesis. By blending Doppler imaging with thoracic ultrasound, this protocol offers procedural clarity and boosts patient safety. A must-read for clinicians that could make a big difference in your next case! 📖 Read more: 🦋 Follow us on BlueSky: #Ultrasound #POCUS #POCUSJournal #Procedures #MedTwitter #MedEd

POCUS Journal

18,453 次观看 • 1 年前

Monday basic surgical tip: be careful when you perform knots with the instruments in your hands and the needle holder with the needle in it ⤵️🪡💥! Because you can turn the needle easily in to a stab and have you or generate in your surgical staff an accidental needle puncture!
0:20

Monday basic surgical tip: be careful when you perform knots with the instruments in your hands and the needle holder with the needle in it ⤵️🪡💥! Because you can turn the needle easily in to a stab and have you or generate in your surgical staff an accidental needle puncture!

Dr Luis Felipe Cabrera Vargas MD FACS

44,001 次观看 • 2 年前

Congratulations to Dr. Amy Fraser and the POCUS_CERC team on the introduction of the DIVOT protocol in the latest POCUS Journal! This innovative approach uses Doppler to visualize and avoid intercostal arteries prior to thoracentesis—advancing procedural safety. IU Pulmonary and Critical Care Fellowship IU School of Medicine NephroPOCUS Read the full article here--> 🔗 #POCUS #Ultrasound #ZeroHarm #MedTwitter
0:50

Congratulations to Dr. Amy Fraser and the POCUS_CERC team on the introduction of the DIVOT protocol in the latest POCUS Journal! This innovative approach uses Doppler to visualize and avoid intercostal arteries prior to thoracentesis—advancing procedural safety. IU Pulmonary and Critical Care Fellowship IU School of Medicine NephroPOCUS Read the full article here--> 🔗 #POCUS #Ultrasound #ZeroHarm #MedTwitter

Pulmonary-POCUS

15,801 次观看 • 1 年前

As part of enhanced security protocols, all individuals, including police officers, bringing patients to hospital, particularly to emergency units, will be required to present and have their identification documents recorded. Going forward, no patient will be admitted if dropped off by unidentified or anonymous persons. This policy is critical in safeguarding both patients and healthcare staff and in preventing cases of abandonment, impersonation or criminal activity within our health facilities.
0:54

As part of enhanced security protocols, all individuals, including police officers, bringing patients to hospital, particularly to emergency units, will be required to present and have their identification documents recorded. Going forward, no patient will be admitted if dropped off by unidentified or anonymous persons. This policy is critical in safeguarding both patients and healthcare staff and in preventing cases of abandonment, impersonation or criminal activity within our health facilities.

Hon. Aden Duale, EGH

194,774 次观看 • 1 年前

Point-of-care ultrasonography (#POCUS) is a noninvasive bedside imaging modality used to assess intravascular volume status in hospitalized or emergency department patients with possible #VolumeOverload. POCUS evaluates the inferior vena cava, internal jugular vein, and lung parenchyma with high-frequency linear, low-frequency phased-array, and low-frequency curvilinear probes.
0:51

Point-of-care ultrasonography (#POCUS) is a noninvasive bedside imaging modality used to assess intravascular volume status in hospitalized or emergency department patients with possible #VolumeOverload. POCUS evaluates the inferior vena cava, internal jugular vein, and lung parenchyma with high-frequency linear, low-frequency phased-array, and low-frequency curvilinear probes.

JAMA

161,383 次观看 • 6 个月前

Robotic technology is boosting accuracy and reducing complications in lung cancer surgery. @WesStreeting saw this innovation in action Guy's and St Thomas' Breakthroughs like this are central to the National Cancer Plan, diagnosing cancer sooner and improving treatment.
1:23

Robotic technology is boosting accuracy and reducing complications in lung cancer surgery. @WesStreeting saw this innovation in action Guy's and St Thomas' Breakthroughs like this are central to the National Cancer Plan, diagnosing cancer sooner and improving treatment.

Department of Health and Social Care

10,838 次观看 • 7 个月前

‼️ Video ‼️ The MMC for Health and Social Development, Cllr Ennie Makhafola along with the MMC for Public Safety, Cllr at Jeppe Clinic listening to healthcare workers and patients, wherein a healthcare worker shared how their safety had been put at risk when a patient threatened them with a knife on a Saturday. In response, the MMC for Health and Social Development, Cllr Ennie Makhafola emphasized the urgent need for mutual respect between patients and healthcare workers, whereas the MMC for Public Safety, Cllr reaffirmed that safety measures will be strengthened to protect staff while ensuring that patients continue to receive dignified care in Jeppe Clinic.
4:15

‼️ Video ‼️ The MMC for Health and Social Development, Cllr Ennie Makhafola along with the MMC for Public Safety, Cllr at Jeppe Clinic listening to healthcare workers and patients, wherein a healthcare worker shared how their safety had been put at risk when a patient threatened them with a knife on a Saturday. In response, the MMC for Health and Social Development, Cllr Ennie Makhafola emphasized the urgent need for mutual respect between patients and healthcare workers, whereas the MMC for Public Safety, Cllr reaffirmed that safety measures will be strengthened to protect staff while ensuring that patients continue to receive dignified care in Jeppe Clinic.

COJ MMC for Health and Social Development

43,286 次观看 • 11 个月前

Ghazal is one of five child patients from #Gaza whose medical evacuation to Belgium and Romania was supported by World Health Organization (WHO) last Monday. Since October 2023, 13,285 patients, including 6285 children have been medically evacuated from Gaza to receive treatment abroad. We thank 🇧🇪 and 🇷🇴 for their continued solidarity with critical patients from Gaza. But as many more children and seriously ill patients need specailsed health care abroad, we continue to call for reopening of patient referral to health facilities in the West Bank, including East Jerusalem, and for more countries to accept patients for medical care not yet available in Gaza.
1:19

Ghazal is one of five child patients from #Gaza whose medical evacuation to Belgium and Romania was supported by World Health Organization (WHO) last Monday. Since October 2023, 13,285 patients, including 6285 children have been medically evacuated from Gaza to receive treatment abroad. We thank 🇧🇪 and 🇷🇴 for their continued solidarity with critical patients from Gaza. But as many more children and seriously ill patients need specailsed health care abroad, we continue to call for reopening of patient referral to health facilities in the West Bank, including East Jerusalem, and for more countries to accept patients for medical care not yet available in Gaza.

Tedros Adhanom Ghebreyesus

43,888 次观看 • 7 天前

Today, World Health Organization (WHO) supported the medical evacuation of 47 patients and 129 companions from #Gaza, despite the ongoing challenges to humanitarian operations and access constraints. Patients travelled to: - Spain: 13 child and one adult patients - Türkiye: 2 adult patients - France: 4 child and one adult patients - Norway: 6 child and 2 adult patients - Jordan: 18 child patients We are grateful to all the governments and health workers for their support and specialised care for the critical patients from Gaza. Over 14,000 patients are still in need of urgent care. We urge more countries to step forward to accept patients for medical evacuations. Ceasefire!
1:42

Today, World Health Organization (WHO) supported the medical evacuation of 47 patients and 129 companions from #Gaza, despite the ongoing challenges to humanitarian operations and access constraints. Patients travelled to: - Spain: 13 child and one adult patients - Türkiye: 2 adult patients - France: 4 child and one adult patients - Norway: 6 child and 2 adult patients - Jordan: 18 child patients We are grateful to all the governments and health workers for their support and specialised care for the critical patients from Gaza. Over 14,000 patients are still in need of urgent care. We urge more countries to step forward to accept patients for medical evacuations. Ceasefire!

Tedros Adhanom Ghebreyesus

36,172 次观看 • 1 年前

What if Cures Exist? 🚨 Dr Burzynski 50 Years Ago Cured Cancer with Peptide “Antineoplaston” - In the 1970s, Dr. Stanislaw Burzynski identified peptides (antineoplastons) in human blood and urine, theorizing they could suppress cancer by restoring defective tumor-suppressor genes - In 1986, Burzynski presented 40 cured cancer patients to the Texas Medical Board. The FDA tried to then take his medical license. 30+ congressmen wrote the FDA to allow clinical trials to continue. The judge declared a mistrial and the FDA dropped all charges. - Small phase II trials at the Burzynski Clinic (e.g., 2003, 2006) reported 25–50% response rates in aggressive brain tumors like glioblastoma and brainstem glioma, with some patients surviving 5–20+ years, exceeding typical prognoses. - The Burzynski Patient Group cite cases like a 2014 medulloblastoma patient surviving over 20 years post-treatment, with autopsies reportedly showing no cancer in some deceased patients. - Lab studies suggest antineoplastons induce cancer cell differentiation and inhibit tumor growth, offering a non-toxic alternative to chemotherapy with fewer severe side effects in some cases. - Supporters, including high-profile figures and documentaries, argue Burzynski’s work has been unfairly suppressed, pointing to over 245 patents and ongoing clinic operations as evidence of efficacy.
2:20

What if Cures Exist? 🚨 Dr Burzynski 50 Years Ago Cured Cancer with Peptide “Antineoplaston” - In the 1970s, Dr. Stanislaw Burzynski identified peptides (antineoplastons) in human blood and urine, theorizing they could suppress cancer by restoring defective tumor-suppressor genes - In 1986, Burzynski presented 40 cured cancer patients to the Texas Medical Board. The FDA tried to then take his medical license. 30+ congressmen wrote the FDA to allow clinical trials to continue. The judge declared a mistrial and the FDA dropped all charges. - Small phase II trials at the Burzynski Clinic (e.g., 2003, 2006) reported 25–50% response rates in aggressive brain tumors like glioblastoma and brainstem glioma, with some patients surviving 5–20+ years, exceeding typical prognoses. - The Burzynski Patient Group cite cases like a 2014 medulloblastoma patient surviving over 20 years post-treatment, with autopsies reportedly showing no cancer in some deceased patients. - Lab studies suggest antineoplastons induce cancer cell differentiation and inhibit tumor growth, offering a non-toxic alternative to chemotherapy with fewer severe side effects in some cases. - Supporters, including high-profile figures and documentaries, argue Burzynski’s work has been unfairly suppressed, pointing to over 245 patents and ongoing clinic operations as evidence of efficacy.

MJTruthUltra

25,116 次观看 • 10 个月前

" Patients are coming to hospitals with Multiple STDs"- Dr. Goody Gor on the increase in STD infections in kenya.The 2025 reports on STDs highlight a "worrying" global and regional surge in infection rates, particularly for syphilis and drug-resistant gonorrhoea!
1:31

" Patients are coming to hospitals with Multiple STDs"- Dr. Goody Gor on the increase in STD infections in kenya.The 2025 reports on STDs highlight a "worrying" global and regional surge in infection rates, particularly for syphilis and drug-resistant gonorrhoea!

The Kenyan Vigilante

31,919 次观看 • 5 个月前

We’re putting America first and improving access to medicines with $500B in historic manufacturing investments, supporting 10 million Americans annually with patient assistance resources and a new website to connect patients with manufacturers’ direct purchase programs.
2:19

We’re putting America first and improving access to medicines with $500B in historic manufacturing investments, supporting 10 million Americans annually with patient assistance resources and a new website to connect patients with manufacturers’ direct purchase programs.

Stephen J. Ubl

871,765 次观看 • 11 个月前

World-first: Sunnybrook and The Hospital for Sick Children (SickKids) are the first in the world to use MRI-guided focused ultrasound to deliver chemotherapy in Diffuse Intrinsic Pontine Glioma, an aggressive and terminal pediatric brain tumour. Read more about the trial:
1:13

World-first: Sunnybrook and The Hospital for Sick Children (SickKids) are the first in the world to use MRI-guided focused ultrasound to deliver chemotherapy in Diffuse Intrinsic Pontine Glioma, an aggressive and terminal pediatric brain tumour. Read more about the trial:

Sunnybrook Health Sciences Centre

208,763 次观看 • 3 年前

🚑 Shock Index (SI): A Vital Tool in Critical Care 🚑 1️⃣ Introduction: The Shock Index is the ratio of heart rate to systolic blood pressure. It's a simple yet powerful tool to identify patients at risk of shock, a life-threatening condition where the body's organs don't receive enough oxygenated blood. 2️⃣ History: First introduced in 1967, by Allgöwer and Buri, as a quick, noninvasive method to determine the degree of hypovolemia in hemorrhagic shock. It's been validated in various settings, from the battlefield to the emergency room, and has proven to be a reliable predictor of patient outcomes. 3️⃣ Patients & Usage: Trauma Patients: Quick assessment of blood loss and severity. Cardiac Patients: Helps in identifying heart-related shock. Sepsis: Early detection of septic shock. Pregnancy: Useful in assessing the risk of complications. Pediatrics: Adapted for use in children with modified values. 4️⃣ How to Calculate: SI = Heart Rate / Systolic Blood Pressure Normal SI: 0.5 - 0.7 Elevated SI (>0.9): Increased risk of shock and mortality. 5️⃣ Advantages: Easy to calculate. Rapid assessment tool. Guides resuscitation efforts. 6️⃣ Limitations: Not a standalone diagnostic tool. May vary with age, medications, and underlying conditions. 7️⃣ Conclusion: The Shock Index is an essential part of modern emergency medicine. By providing a quick snapshot of a patient's physiological state, it enables timely intervention and can save lives. 🩺 Share this post with your fellow healthcare professionals to spread awareness about this crucial tool in trauma care! 🩺
0:41

🚑 Shock Index (SI): A Vital Tool in Critical Care 🚑 1️⃣ Introduction: The Shock Index is the ratio of heart rate to systolic blood pressure. It's a simple yet powerful tool to identify patients at risk of shock, a life-threatening condition where the body's organs don't receive enough oxygenated blood. 2️⃣ History: First introduced in 1967, by Allgöwer and Buri, as a quick, noninvasive method to determine the degree of hypovolemia in hemorrhagic shock. It's been validated in various settings, from the battlefield to the emergency room, and has proven to be a reliable predictor of patient outcomes. 3️⃣ Patients & Usage: Trauma Patients: Quick assessment of blood loss and severity. Cardiac Patients: Helps in identifying heart-related shock. Sepsis: Early detection of septic shock. Pregnancy: Useful in assessing the risk of complications. Pediatrics: Adapted for use in children with modified values. 4️⃣ How to Calculate: SI = Heart Rate / Systolic Blood Pressure Normal SI: 0.5 - 0.7 Elevated SI (>0.9): Increased risk of shock and mortality. 5️⃣ Advantages: Easy to calculate. Rapid assessment tool. Guides resuscitation efforts. 6️⃣ Limitations: Not a standalone diagnostic tool. May vary with age, medications, and underlying conditions. 7️⃣ Conclusion: The Shock Index is an essential part of modern emergency medicine. By providing a quick snapshot of a patient's physiological state, it enables timely intervention and can save lives. 🩺 Share this post with your fellow healthcare professionals to spread awareness about this crucial tool in trauma care! 🩺

𝗥𝗲𝘀𝘂𝘀𝗠𝗲𝗱

54,144 次观看 • 3 年前

PHOTON COUNTING CT is NOT a better CT It is a NEW imaging modality Photon Counting CT (PCCT) represents a transformative leap in medical imaging, not only as a molecular imaging modality but also as a technology offering ultra-high resolution and functional imaging capabilities. It is fundamentally more than just an enhanced version of traditional CT—PCCT introduces new ways of seeing and understanding the human body, providing critical insights at the molecular, structural, and functional levels. This positions PCCT as a unique imaging modality that requires a fresh approach to technical implementation, operational workflows, and financial planning. Despite the larger upfront investment, PCCT’s ability to drastically reduce downstream healthcare costs makes it a highly valuable investment in the long run. 1. Technical Innovations • Molecular Imaging and Energy Discrimination: Unlike traditional CT, which simply measures the total absorbed energy, PCCT counts individual X-ray photons and differentiates their energy levels. This allows for precise molecular imaging, revealing the composition of tissues and materials at a biochemical level. By distinguishing between different tissue types and contrast agents, PCCT opens up new diagnostic possibilities, such as identifying molecular biomarkers in tumors or distinguishing between stable and unstable plaque in coronary arteries. This capability shifts the focus of imaging from purely anatomical to both anatomical and molecular, offering more comprehensive diagnostic information. • Ultra-High Spatial Resolution: PCCT features significantly smaller detector elements compared to conventional CT scanners, allowing for ultra-high resolution imaging. This means clinicians can visualize fine structures such as microcalcifications in arteries, small lesions in soft tissues, or the intricate architecture of bones. This level of detail was previously unattainable with traditional CT. When combined with molecular imaging, this ultra-high resolution allows for the precise localization and characterization of disease at very early stages, which is essential for early diagnosis and intervention. • Functional Imaging Capabilities: PCCT also excels as a functional imaging modality. By capturing energy-resolved information, PCCT can provide insights into tissue functionality and dynamic physiological processes. For instance, it can detect changes in blood flow, tissue perfusion, and oxygenation without the need for additional contrast agents or scans. This functionality allows for real-time assessment of physiological processes, making it particularly valuable in cardiology, oncology, and neurology for evaluating organ function and monitoring disease progression. • Reduced Noise and Artifact Reduction: Photon-counting technology dramatically reduces electronic noise and imaging artifacts, such as beam hardening, resulting in clearer and more accurate images. The ability to deliver ultra-high resolution images with minimal artifacts improves diagnostic accuracy, reducing the need for repeat scans and ensuring that even subtle abnormalities are detected. 2. Operational Considerations • New Workflow for Molecular, High-Resolution, and Functional Imaging: The integration of molecular, ultra-high resolution, and functional imaging into routine clinical workflows introduces complexity that requires adaptation. Radiologists and technicians need specialized training to interpret and analyze multi-energy datasets that include molecular and functional information. PCCT produces a vast amount of detailed data, requiring clinicians to adopt new imaging protocols and refine their diagnostic approaches to fully leverage its capabilities. • Post-Processing and Data Management: PCCT generates richer, more complex datasets, which necessitates advanced post-processing tools and data management systems. Existing PACS and imaging software may not be equipped to handle such large volumes of data or to process functional and molecular information effectively. This means healthcare institutions must invest in robust IT infrastructure, including upgraded software and storage solutions, as well as provide additional training for staff on new imaging analysis techniques. • Revised Clinical Protocols: The molecular, functional, and ultra-high resolution imaging capabilities of PCCT will likely prompt changes in clinical protocols. For instance, the need for contrast agents may be reduced, simplifying patient preparation and decreasing the risk of adverse reactions. Additionally, the ability to monitor physiological functions in real-time through functional imaging could lead to more dynamic diagnostic procedures, such as assessing the effectiveness of interventions or treatments in real-time. 3. Financial Impact • Higher Initial Investment: PCCT systems are more expensive than traditional CT scanners due to their advanced technology, which includes photon-counting detectors and the computational power required for high-resolution, molecular, and functional imaging. While this upfront cost is significant, it is crucial to view it in the broader context of the downstream benefits and cost reductions that PCCT offers. • Downstream Cost Reductions: Although the initial capital investment is higher, PCCT’s ability to combine molecular, functional, and ultra-high resolution imaging leads to substantial reductions in downstream healthcare costs. Its superior diagnostic accuracy minimizes the need for follow-up tests, repeat scans, or invasive diagnostic procedures, such as diagnostic coronary angiographies. For example, in cardiology, PCCT can precisely differentiate between types of coronary plaque, reducing the need for invasive procedures to assess risk. • Lower Overall Healthcare Expenditures: By enabling earlier, more accurate diagnoses, PCCT can reduce the overall cost of patient care. Early detection of disease, particularly through its molecular and functional imaging capabilities, allows for more targeted treatments, potentially preventing the need for more aggressive and expensive interventions down the line. For instance, early-stage tumor detection via molecular imaging could lead to less invasive treatments, reducing hospital stays and improving patient outcomes, ultimately driving down healthcare costs. • Increased ROI Through Enhanced Patient Outcomes: Over time, the combination of molecular, functional, and ultra-high resolution imaging enhances diagnostic precision, which translates into better patient outcomes. Improved diagnostic accuracy reduces the incidence of unnecessary procedures, minimizes treatment delays, and results in more personalized and effective care. This leads to increased patient satisfaction, better healthcare outcomes, and greater patient throughput—all factors that improve the institution’s return on investment (ROI). • Competitive Advantage and New Revenue Streams: By adopting PCCT, healthcare institutions position themselves at the forefront of advanced imaging technologies. The ability to offer molecular, functional, and ultra-high resolution imaging creates a competitive advantage, attracting more complex and high-value cases. This can boost the institution’s reputation for excellence in diagnostics, leading to increased referrals, new patient populations, and expanded revenue opportunities. Summary Photon Counting CT (PCCT) is not just an evolution of existing CT technology—it is a molecular, ultra-high resolution, and functional imaging modality that fundamentally transforms the diagnostic landscape. Its ability to capture detailed molecular data, visualize minute anatomical structures with ultra-high resolution, and provide real-time functional imaging opens new possibilities for earlier and more precise diagnoses. While the financial investment in PCCT is larger, the reduction in downstream healthcare costs through improved diagnostic accuracy, fewer unnecessary interventions, and earlier disease detection far outweighs the initial expense. For institutions committed to advancing patient care and improving long-term financial outcomes, PCCT is an essential investment in the future of medical imaging. The video attached shows a patient accessing the Hospital for ACS. PCCT can provide ALL the imaging information of the concurrent imaging modalities (CXR, CAG, Echo, CMR) that you see around it... that's a lot! #PhotonCountingCT #MolecularImaging #UltraHighResolution #FunctionalImaging #FutureOfImaging #AdvancedMedicalImaging #EarlyDiseaseDetection #InnovativeCT #CuttingEdgeHealthcare #PrecisionDiagnostics #HealthcareInnovation #MedicalTechnology #CostEffectiveImaging #NextGenCT #PatientCareRevolution
1:10

PHOTON COUNTING CT is NOT a better CT It is a NEW imaging modality Photon Counting CT (PCCT) represents a transformative leap in medical imaging, not only as a molecular imaging modality but also as a technology offering ultra-high resolution and functional imaging capabilities. It is fundamentally more than just an enhanced version of traditional CT—PCCT introduces new ways of seeing and understanding the human body, providing critical insights at the molecular, structural, and functional levels. This positions PCCT as a unique imaging modality that requires a fresh approach to technical implementation, operational workflows, and financial planning. Despite the larger upfront investment, PCCT’s ability to drastically reduce downstream healthcare costs makes it a highly valuable investment in the long run. 1. Technical Innovations • Molecular Imaging and Energy Discrimination: Unlike traditional CT, which simply measures the total absorbed energy, PCCT counts individual X-ray photons and differentiates their energy levels. This allows for precise molecular imaging, revealing the composition of tissues and materials at a biochemical level. By distinguishing between different tissue types and contrast agents, PCCT opens up new diagnostic possibilities, such as identifying molecular biomarkers in tumors or distinguishing between stable and unstable plaque in coronary arteries. This capability shifts the focus of imaging from purely anatomical to both anatomical and molecular, offering more comprehensive diagnostic information. • Ultra-High Spatial Resolution: PCCT features significantly smaller detector elements compared to conventional CT scanners, allowing for ultra-high resolution imaging. This means clinicians can visualize fine structures such as microcalcifications in arteries, small lesions in soft tissues, or the intricate architecture of bones. This level of detail was previously unattainable with traditional CT. When combined with molecular imaging, this ultra-high resolution allows for the precise localization and characterization of disease at very early stages, which is essential for early diagnosis and intervention. • Functional Imaging Capabilities: PCCT also excels as a functional imaging modality. By capturing energy-resolved information, PCCT can provide insights into tissue functionality and dynamic physiological processes. For instance, it can detect changes in blood flow, tissue perfusion, and oxygenation without the need for additional contrast agents or scans. This functionality allows for real-time assessment of physiological processes, making it particularly valuable in cardiology, oncology, and neurology for evaluating organ function and monitoring disease progression. • Reduced Noise and Artifact Reduction: Photon-counting technology dramatically reduces electronic noise and imaging artifacts, such as beam hardening, resulting in clearer and more accurate images. The ability to deliver ultra-high resolution images with minimal artifacts improves diagnostic accuracy, reducing the need for repeat scans and ensuring that even subtle abnormalities are detected. 2. Operational Considerations • New Workflow for Molecular, High-Resolution, and Functional Imaging: The integration of molecular, ultra-high resolution, and functional imaging into routine clinical workflows introduces complexity that requires adaptation. Radiologists and technicians need specialized training to interpret and analyze multi-energy datasets that include molecular and functional information. PCCT produces a vast amount of detailed data, requiring clinicians to adopt new imaging protocols and refine their diagnostic approaches to fully leverage its capabilities. • Post-Processing and Data Management: PCCT generates richer, more complex datasets, which necessitates advanced post-processing tools and data management systems. Existing PACS and imaging software may not be equipped to handle such large volumes of data or to process functional and molecular information effectively. This means healthcare institutions must invest in robust IT infrastructure, including upgraded software and storage solutions, as well as provide additional training for staff on new imaging analysis techniques. • Revised Clinical Protocols: The molecular, functional, and ultra-high resolution imaging capabilities of PCCT will likely prompt changes in clinical protocols. For instance, the need for contrast agents may be reduced, simplifying patient preparation and decreasing the risk of adverse reactions. Additionally, the ability to monitor physiological functions in real-time through functional imaging could lead to more dynamic diagnostic procedures, such as assessing the effectiveness of interventions or treatments in real-time. 3. Financial Impact • Higher Initial Investment: PCCT systems are more expensive than traditional CT scanners due to their advanced technology, which includes photon-counting detectors and the computational power required for high-resolution, molecular, and functional imaging. While this upfront cost is significant, it is crucial to view it in the broader context of the downstream benefits and cost reductions that PCCT offers. • Downstream Cost Reductions: Although the initial capital investment is higher, PCCT’s ability to combine molecular, functional, and ultra-high resolution imaging leads to substantial reductions in downstream healthcare costs. Its superior diagnostic accuracy minimizes the need for follow-up tests, repeat scans, or invasive diagnostic procedures, such as diagnostic coronary angiographies. For example, in cardiology, PCCT can precisely differentiate between types of coronary plaque, reducing the need for invasive procedures to assess risk. • Lower Overall Healthcare Expenditures: By enabling earlier, more accurate diagnoses, PCCT can reduce the overall cost of patient care. Early detection of disease, particularly through its molecular and functional imaging capabilities, allows for more targeted treatments, potentially preventing the need for more aggressive and expensive interventions down the line. For instance, early-stage tumor detection via molecular imaging could lead to less invasive treatments, reducing hospital stays and improving patient outcomes, ultimately driving down healthcare costs. • Increased ROI Through Enhanced Patient Outcomes: Over time, the combination of molecular, functional, and ultra-high resolution imaging enhances diagnostic precision, which translates into better patient outcomes. Improved diagnostic accuracy reduces the incidence of unnecessary procedures, minimizes treatment delays, and results in more personalized and effective care. This leads to increased patient satisfaction, better healthcare outcomes, and greater patient throughput—all factors that improve the institution’s return on investment (ROI). • Competitive Advantage and New Revenue Streams: By adopting PCCT, healthcare institutions position themselves at the forefront of advanced imaging technologies. The ability to offer molecular, functional, and ultra-high resolution imaging creates a competitive advantage, attracting more complex and high-value cases. This can boost the institution’s reputation for excellence in diagnostics, leading to increased referrals, new patient populations, and expanded revenue opportunities. Summary Photon Counting CT (PCCT) is not just an evolution of existing CT technology—it is a molecular, ultra-high resolution, and functional imaging modality that fundamentally transforms the diagnostic landscape. Its ability to capture detailed molecular data, visualize minute anatomical structures with ultra-high resolution, and provide real-time functional imaging opens new possibilities for earlier and more precise diagnoses. While the financial investment in PCCT is larger, the reduction in downstream healthcare costs through improved diagnostic accuracy, fewer unnecessary interventions, and earlier disease detection far outweighs the initial expense. For institutions committed to advancing patient care and improving long-term financial outcomes, PCCT is an essential investment in the future of medical imaging. The video attached shows a patient accessing the Hospital for ACS. PCCT can provide ALL the imaging information of the concurrent imaging modalities (CXR, CAG, Echo, CMR) that you see around it... that's a lot! #PhotonCountingCT #MolecularImaging #UltraHighResolution #FunctionalImaging #FutureOfImaging #AdvancedMedicalImaging #EarlyDiseaseDetection #InnovativeCT #CuttingEdgeHealthcare #PrecisionDiagnostics #HealthcareInnovation #MedicalTechnology #CostEffectiveImaging #NextGenCT #PatientCareRevolution

Dr. Filippo Cademartiri

11,849 次观看 • 1 年前

The amazing dedicated team at CSSIFM treating our cancer patients with NK cells in clinical trials. So many requests from patients who have failed all standards of care and they are working so hard to file for FDA authorization as many single patient INDs as we can. Happy Easter and stay safe
0:54

The amazing dedicated team at CSSIFM treating our cancer patients with NK cells in clinical trials. So many requests from patients who have failed all standards of care and they are working so hard to file for FDA authorization as many single patient INDs as we can. Happy Easter and stay safe

Dr. Pat Soon-Shiong

32,967 次观看 • 5 个月前

Thank you to all at UCLH and Macmillan Cancer Support for your tireless work to provide cancer patients with the best care and support. Marking His Majesty’s return to public duties, The King and Queen spent time with patients to hear about their ongoing treatment and support.
1:02

Thank you to all at UCLH and Macmillan Cancer Support for your tireless work to provide cancer patients with the best care and support. Marking His Majesty’s return to public duties, The King and Queen spent time with patients to hear about their ongoing treatment and support.

The Royal Family

308,924 次观看 • 2 年前